RepliCel Life Sciences Inc. has postponed the filing of its interim financial statements and management's discussion and analysis for the six-month period ended June 30, 2020, due to logistics and delays caused by the COVID-19 pandemic. The Company relied on the relief provided by British Columbia Instrument 51-517, Alberta Securities commission Blanket Order 51-519 and Ontario Instrument 51-505 that allows it to delay the filing of its Interim Documents which are due to be filed on or before August 31, 2020, pursuant to sections 4.2 and 5.1(2) of National Instrument 51-102. In response to the coronavirus disease 2019 pandemic, securities regulatory authorities in Canada have granted a blanket exemption allowing issuers an additional 45 days to complete their regulatory filings.